Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-09-09 09:09 am Purchase | 13G | Akero Therapeutics Inc. AKRO | WELLINGTON MANAGEMENT GROUP LLP | 7,029,624 10.12% | 4,147,635 (+143.92%) | View |
| 2024-06-10 4:17 pm Purchase | 13G | Akero Therapeutics Inc. AKRO | JANUS HENDERSON GROUP PLC JHG | 6,950,418 10.1% | 2,644,017 (+61.40%) | View |
| 2024-03-15 10:08 am Purchase | 13G | Akero Therapeutics Inc. AKRO | GENERAL ATLANTIC L.P. | 5,233,989 7.7% | 5,233,989 (New Position) | View |
| 2024-02-14 4:26 pm Sale | 13G | Akero Therapeutics Inc. AKRO | Redmile Group LLC | 1,109,476 2% | -1,523,436 (-57.86%) | View |
| 2024-02-14 4:21 pm Unchanged | 13G | Akero Therapeutics Inc. AKRO | BAKER BROS. ADVISORS LP | 2,368,378 4.3% | 0 (Unchanged) | View |
| 2024-02-14 2:19 pm Unchanged | 13G | Akero Therapeutics Inc. AKRO | PFIZER INC PFE | 2,525,252 4.53% | 0 (Unchanged) | View |
| 2024-02-14 10:03 am Purchase | 13G | Akero Therapeutics Inc. AKRO | PRICE T ROWE ASSOCIATES INC | 3,681,209 6.6% | 1,280,172 (+53.32%) | View |
| 2024-02-14 07:06 am Purchase | 13G | Akero Therapeutics Inc. AKRO | RTW INVESTMENTS LP | 3,592,759 6.4% | 3,592,759 (New Position) | View |
| 2024-02-13 9:40 pm Sale | 13G | Akero Therapeutics Inc. AKRO | Avidity Partners Management LP | 235,000 0.4% | -3,590,000 (-93.86%) | View |
| 2024-02-13 6:30 pm Purchase | 13G | Akero Therapeutics Inc. AKRO | ALKEON CAPITAL MANAGEMENT LLC | 3,764,220 6.8% | 520,305 (+16.04%) | View |
| 2024-02-13 4:58 pm Purchase | 13G | Akero Therapeutics Inc. AKRO | VANGUARD GROUP INC | 3,085,048 5.54% | 3,085,048 (New Position) | View |
| 2024-02-13 11:31 am Purchase | 13G | Akero Therapeutics Inc. AKRO | JANUS HENDERSON GROUP PLC JHG | 4,306,401 7.7% | 966,227 (+28.93%) | View |
| 2024-02-08 10:05 am Purchase | 13G | Akero Therapeutics Inc. AKRO | WELLINGTON MANAGEMENT GROUP LLP | 2,881,989 5.17% | 2,005,890 (+228.96%) | View |
| 2024-02-07 07:23 am Sale | 13G | Akero Therapeutics Inc. AKRO | ADAGE CAPITAL PARTNERS GP L.L.C. | 275,000 0.49% | -2,527,627 (-90.19%) | View |
| 2024-01-26 11:49 am Purchase | 13G | Akero Therapeutics Inc. AKRO | BlackRock Inc. BLK | 4,180,507 7.5% | 1,421,978 (+51.55%) | View |
| 2024-01-25 09:36 am Purchase | 13G | Akero Therapeutics Inc. AKRO | STATE STREET CORP STT | 5,122,895 9.2% | 2,621,926 (+104.84%) | View |
| 2023-09-12 4:30 pm Sale | 13G | Akero Therapeutics Inc. AKRO | Skorpios Trust | 0 0% | -3,271,829 (Position Closed) | View |
| 2023-04-10 4:59 pm Purchase | 13G | Akero Therapeutics Inc. AKRO | ADAGE CAPITAL PARTNERS GP L.L.C. | 2,802,627 5.97% | 2,802,627 (New Position) | View |
| 2023-02-14 4:31 pm Sale | 13G | Akero Therapeutics Inc. AKRO | Atlas Venture Fund XI L.P. | 467,529 1% | -1,496,000 (-76.19%) | View |
| 2023-02-14 4:23 pm Purchase | 13G | Akero Therapeutics Inc. AKRO | Redmile Group LLC | 2,632,912 5.6% | 1,030,627 (+64.32%) | View |